Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.

Bennett Levitan, MD, PhD, Zhong Yuan, MD, PhD, Alexander GG Turpie, MD, Richard J Friedman, MD, Martin Homering, MSPH, Jesse A Berlin, ScD, Scott D Berkowitz, MD, FACP, Peter M DiBattiste, MD, FACC

Blood (2009) 114 (22): 169.

https://doi.org/10.1182/blood.V114.22.169.169

Published: 2009

Journal Articles

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Jeffrey I. Weitz, MD, FACP, FRCP, Charlie Cao, Ph.D., Bengt Eriksson, MD, William D. Fisher, MD, Stuart Kupfer, MD, Gary E Raskob, PhD, Jeffrey Spaeder, MD, Alexander GG Turpie, MD

Blood (2009) 114 (22): 170.

https://doi.org/10.1182/blood.V114.22.170.170

Published: 2009

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD, Kenneth A. Bauer, MD, Bruce Davidson, MD, Michael Gent, MD, Louis Kwong, MD, Michael Rud Lassen, MD, Fred Cushner, MD, Paul Lotke, MD, Scott D. Berkowitz, MD, FACP, Tiemo Joerg Bandel, Frank Misselwitz, MD, William Fisher, MD

Blood (2008) 112 (11): 35.

https://doi.org/10.1182/blood.V112.11.35.35

Published: 2008

Journal Articles

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

Alexander GG Turpie, MD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Victor F Tapson, MD, Manuel Monreal, MD, Meyer Michel Samama, MD, PharmD, Roger D Yusen, MD, MPH

Blood (2008) 112 (11): 433.

https://doi.org/10.1182/blood.V112.11.433.433

Published: 2008

Journal Articles

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

Roger D Yusen, Russell D Hull, Sebastian M Schellong, Victor F Tapson, Manuel Monreal, Michel Meyer Samama, Min Chen, Alexander GG Turpie

Blood (2008) 112 (11): 438.

https://doi.org/10.1182/blood.V112.11.438.438

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Bengt Eriksson, MD, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, MD, Martin Homering, Torsten Westermeier, PhD, Michael Gent, DSc

Blood (2008) 112 (11): 36.

https://doi.org/10.1182/blood.V112.11.36.36

Published: 2008

Journal Articles

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Frederick A Anderson, Jr., PhD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Bruno Deslandes, Victor F Tapson, MD, Meyer Michel Samama, MD, PharmD, Alexander GG Turpie, MD, Roger D Yusen, MD, MPH, Herve Decousus, MD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Manuel Monreal, MD

Blood (2008) 112 (11): 1981.

https://doi.org/10.1182/blood.V112.11.1981.1981

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

Bengt Eriksson, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, Martin Homering, Torsten Westermeier, Michael Gent, MD

Blood (2008) 112 (11): 1986.

https://doi.org/10.1182/blood.V112.11.1986.1986

Published: 2008

NARROW

Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only